Next Article in Journal
Efficacy and Safety of Combined Androgen Blockade with Antiandrogen for Advanced Prostate Cancer
Previous Article in Journal
Efficacy of Second-Line Chemotherapy after a First-Line Triplet in Patients with Metastatic Colorectal Cancer
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Current Oncology
Volume 26
Issue 1
10.3747/co.26.4135
curroncol-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Prognostic Value of Inflammation-Based Markers in Advanced or Metastatic Neuroendocrine Tumours

by
J. Zou
,
Q. Li
,
F. Kou
,
Y. Zhu
,
M. Lu
,
J. Li
,
Zhihao Lu
* and
Lin Shen
*
Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education–Beijing), Peking University Cancer Hospital and Institute, Beijing 100142, China
*
Authors to whom correspondence should be addressed.
Curr. Oncol. 2019, 26(1), 4135; https://doi.org/10.3747/co.26.4135
Submission received: 3 November 2018 / Revised: 4 December 2018 / Accepted: 9 January 2019 / Published: 1 February 2019

Abstract

Background: The role of systemic inflammation–based markers remains uncertain in advanced or metastatic neuroendocrine tumours (NETS). Methods: Systemic inflammatory factors, such as levels of circulating white blood cells and other blood components, were combined to yield inflammation-based prognostic scores [high-sensitivity inflammation-based Glasgow prognostic score (hSGPS), neutrophil:lymphocyte ratio (NLR), platelet:lymphocyte ratio (PLR), high-sensitivity inflammation-based prognostic index (hSPI), and prognostic nutritional index (PNI)], whose individual values as prognostic markers were retrospectively determined. Univariate and multivariate analyses were used to examine the association of inflammatory markers with overall survival (OS). Results: The study included 135 patients. Univariate analysis revealed that elevated white blood cell count, elevated neutrophil count, low serum albumin, elevated high-sensitivity C-reactive protein, and elevated hSPI, hSGPS, and NLR scores were significantly associated with worse OS. Multivariate analyses demonstrated that, apart from pathology grade and original site of the tumour, elevated hSPI (p = 0.004) was an independent prognostic factor for worse OS. Conclusions: In the present study, elevated pretreatment hSPI was observed to be an independent predictor of shorter OS in patients with inoperable advanced or metastatic NET. The hSPI might thus provide additional guidance for therapeutic decision-making in such patients.
Keywords: neuroendocrine tumours; inflammation; prognostic indices; overall survival neuroendocrine tumours; inflammation; prognostic indices; overall survival

Share and Cite

MDPI and ACS Style

Zou, J.; Li, Q.; Kou, F.; Zhu, Y.; Lu, M.; Li, J.; Lu, Z.; Shen, L. Prognostic Value of Inflammation-Based Markers in Advanced or Metastatic Neuroendocrine Tumours. Curr. Oncol. 2019, 26, 4135. https://doi.org/10.3747/co.26.4135

AMA Style

Zou J, Li Q, Kou F, Zhu Y, Lu M, Li J, Lu Z, Shen L. Prognostic Value of Inflammation-Based Markers in Advanced or Metastatic Neuroendocrine Tumours. Current Oncology. 2019; 26(1):4135. https://doi.org/10.3747/co.26.4135

Chicago/Turabian Style

Zou, J., Q. Li, F. Kou, Y. Zhu, M. Lu, J. Li, Zhihao Lu, and Lin Shen. 2019. "Prognostic Value of Inflammation-Based Markers in Advanced or Metastatic Neuroendocrine Tumours" Current Oncology 26, no. 1: 4135. https://doi.org/10.3747/co.26.4135

APA Style

Zou, J., Li, Q., Kou, F., Zhu, Y., Lu, M., Li, J., Lu, Z., & Shen, L. (2019). Prognostic Value of Inflammation-Based Markers in Advanced or Metastatic Neuroendocrine Tumours. Current Oncology, 26(1), 4135. https://doi.org/10.3747/co.26.4135

Article Metrics

Back to TopTop